Thanks, Larry. Before we review the financial performance for the quarter, the guidance we gave on our last call and past calls excluded the impact of any FX gains and losses and assumed an effective tax rate of 25%. So accordingly, our discussion today excludes any foreign exchange gain or loss for current and prior periods. The comparison periods for the second quarter of 2026 and the third quarter of 2025 also include items that were discussed on those calls and highlighted in our earnings release for those periods. These items have also been excluded from our discussion of the financial results today. You can find a summary of those items in the tables attached to our press release for the third quarter of 2026. So now looking at the income statement, revenue was $132.1 million in the third quarter, up 6% compared to the prior quarter and down 2% year-over-year. Sequentially, we saw growth in demand for our completion products in both the U.S. land and international markets, while service revenue increased in several international regions. The conflicts in both Russia, Ukraine and the Middle East have continued to primarily impact service revenue. Of this revenue, service revenue, which is more international, was $96 million for the quarter, up 2% sequentially and down 5% year-over-year. Our service revenue associated with crude assay services and proprietary studies continue to be impacted by the geopolitical conflicts in the Middle East and Russia, Ukraine, which are the primary reason for the year-over-year decrease. However, growth in other regions outside these affected areas offset some of the impact. Sequentially, service revenue was up as we continue to see increased demand for our reservoir rock and fluid analytical programs in nearly all international regions, including the Middle East. However, the increase was partially offset by a lower level of well completion diagnostic services as several large projects scheduled for the third quarter were delayed due to changes in the client schedule. Product sales, which are more equally tied to North America and international activity were $36.1 million for the quarter and were up 19% sequentially and 8% year-over-year. Sequentially, we saw improved demand for completion products and a growing adoption of our proprietary completion technologies in the U.S. International product sales were also up nicely and up 31% compared to the second quarter. As a reminder, international product sales are typically larger bulk orders and can vary from 1 quarter to another. Additionally, laboratory instrumentation sales were higher in the third quarter compared to the prior quarter. When looking at year-over-year, the growth in product sales was primarily in the U.S. Moving on to cost of services, ex-items for the quarter was 78% of service revenue, which improved from 80% in the prior quarter but increased from 74% last year. Sequential improvement was primarily driven by higher revenue, supported by a relatively fixed cost structure. The year-over-year increase is primarily a result of the company continuing to carry costs in the regions which have been more negatively impacted in 2026 by the escalation of the conflicts in both Middle East and Russia, Ukraine. As discussed on prior calls, the service side of our business has been more affected by geopolitical conflicts and expanded sanctions. Volatility in crude oil prices, along with the continued conflicts in Russia, Ukraine and the Middle East have disrupted regional operations and reduced demand for our crude assay services, which are closely tied to the trading and maritime movement of crude oil and derived products. We will continue to manage our cost structure as effectively as possible as we work through these disruptions in certain regions. Cost of sales ex-items in the third quarter was 83% of revenue, an improvement from 85% in the prior quarter and 88% compared to last year. Sequential improvement was primarily driven by absorption of fixed costs on higher revenue and continued cost control initiatives and manufacturing efficiencies. With these initiatives in place, we anticipate the manufacturing absorption rate in future quarters to be in line with projected product sales. G&A ex-items for the quarter was $11.3 million, which was up slightly compared to the prior quarter and up $600,000 from the same quarter in the prior year. For 2026, we expect G&A ex-items to be approximately $43 million to $45 million. It is also important to note that 100% of our corporate G&A expenses are allocated and absorbed into the financial performance of the reported segments. Depreciation and amortization for the quarter was $3.7 million, relatively flat compared to the prior quarter and the prior year. EBIT ex-items for the quarter was $12.6 million, up from $9.4 million last quarter, yielding an EBIT margin of approximately 10% and expanding 200 basis points from last quarter. Our EBIT for the quarter on a GAAP basis was $12.1 million. Interest expense of $2.8 million for the third quarter is relatively flat compared to the prior quarter and $2.7 million in the same quarter in the prior year. The changes in interest expense were primarily due to changes in average borrowings with variable interest rates during these periods. Income tax expense at an effective tax rate of 25% and ex-items was $2.5 million for the quarter. On a GAAP basis, we recorded tax expense of $3.8 million for the quarter. The effective tax rate will continue to be somewhat sensitive to the geographic mix of earnings across the globe and the impact of items discrete to each quarter. We continue to project the company's effective tax rate to be approximately 25%. Net income ex-items for the quarter was $7.4 million, up sequentially from $5.1 million last quarter, but down from $10.2 million in the third quarter of last year. On a GAAP basis, we had net income of $5.4 million for the quarter. Earnings per diluted share ex-items was $0.16 for the quarter compared to $0.11 in the prior quarter and $0.22 in the third quarter of last year. On a GAAP basis, EPS was $0.12 for the quarter. Turning to the balance sheet. Receivables were $115.6 million, an increase from $108.8 million in the prior quarter. Our DSOs for the third quarter were at 72 days, which improved slightly from the 73 days last quarter. As discussed on prior calls, the timing of collections has been impacted by the ongoing conflicts, and we will continue to remain focused on our collection efforts in these affected regions. Inventory as of September 30, 2026, was $60.7 million, up from $58 million at last quarter end. The increase in inventory during 2026 is primarily associated with increased cost of raw materials. Inventory turns for the quarter improved to 2.0 compared to 1.8 at the last quarter end. With continued focus, we anticipate inventory turns will gradually improve as we progress through the remainder of 2026. And now to the liability side of the balance sheet. Our long-term debt was $114.8 million as of September 30, 2026. And considering cash of $21.4 million, net debt was $93.4 million, which decreased slightly from last quarter. Our leverage ratio is currently just under 1.5 compared to 1.3 last quarter. Our debt is currently comprised of $65 million in senior notes, a term loan of $48.8 million and $1 million outstanding under our bank credit facility. Looking at cash flow for the third quarter of 2026, cash flow from operating activities was $5 million and after paying $3.3 million of CapEx for operations, our free cash flow for the quarter was $1.7 million. As a reminder, the capital expenditures associated with rebuilding our U.K. facility, which are covered by the company's insurance have been excluded in the calculation of free cash flow. In the third quarter of 2026, capital expenditures associated with rebuilding the U.K. facility were $500,000. Looking ahead to the rest of the year, we will continue our strict capital discipline and asset-light business model with capital expenditures primarily targeted at growth opportunities. Excluding the CapEx for rebuilding the U.K. facility, we expect capital expenditures for the full year 2026 to be in the range of $14 million to $16 million. Core Lab's operational leverage to provide the ability to grow revenue and profitability with minimal capital requirements. Capital expenditures for operations has historically ranged from 2% to 4% of revenue even during periods of significant growth. That same level of laboratory infrastructure, intellectual property and leverage exists in the business today. We believe evaluating the company's ability to generate free cash flow and free cash flow yield is an important metric for shareholders when comparing and projecting company's financial results, particularly for those shareholders who utilize discounted cash flow models to assess valuations. I will now turn it over to Gwen for an update on our guidance and outlook.